The active ingredient
in MIGRANAL® (dihydroergotamine mesylate) is commonly used in emergency rooms for a simple
reason: it works. If you’re
one of the nearly 3 out of 4 people dissatisfied with their
current migraine treatment, consider the benefits of MIGRANAL:
MIGRANAL can be used at any time during
a migraine attack, even for morning migraine attacks
MIGRANAL works on both the peripheral and central
components of a migraine attack
86% of MIGRANAL users are migraine–free the next day
MIGRANAL is a nasal spray and works faster than
many oral medications
MIGRANAL can reduce the nausea as well
as the sensitivity to light/sound associated with migraines
MIGRANAL is proven, safe, and effective
DHE, the active ingredient in MIGRANAL, is the treatment most emergency rooms use to treat migraines
Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.
Migranal Nasal Spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina. Migranal also should not be given to patients with uncontrolled hypertension, patients who have used 5-HT1 agonists, ergotamine-containing or ergot-type medications or methysergide within the last 24 hours, or patients with hemiplegic or basilar migraine. Migranal Nasal Spray is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. Migranal Nasal Spray should not be administered to pregnant women or nursing mothers.
Serious cardiac events, including some that have been fatal, have occurred following use of DHE 45 but are extremely rare. During clinical studies and the foreign postmarketing experience with Migranal Nasal Spray, there have been no fatalities due to cardiac events.
The most commonly reported adverse events in clinical trials for Migranal Nasal Spray were rhinitis, altered sense of taste, application site reactions, dizziness, nausea and vomiting. Adverse events associated with discontinuation were rhinitis, dizziness, facial edema, cold sweats, accidental trauma, depression, elective surgery, somnolence, allergy, vomiting, hypotension, and paresthesia.
